Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 1.14.13.9 extracted from

  • Tashiro, T.; Murakami, Y.; Mouri, A.; Imamura, Y.; Nabeshima, T.; Yamamoto, Y.; Saito, K.
    Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions (2017), Behav. Brain Res., 317, 279-285 .
    View publication on PubMed

Organism

Organism UniProt Comment Textmining
Mus musculus Q91WN4
-
-

General Information

General Information Comment Organism
drug target contents of L-tryptophan and monoamines and their metabolites are measured in the serum and hippocampus of kynurenine 3-monooxygenase KO mice. It is investigated whether antidepressants improve the depressive-like behaviors in kynurenine 3-monooxygenase KO mice. KO mice show antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions via abnormality of kynurenine metabolism with good validities as model for major depressive disorder Mus musculus
malfunction contents of L-tryptophan and monoamines and their metabolites are measured in the serum and hippocampus of kynurenine 3-monooxygenase KO mice. It is investigated whether antidepressants improve the depressive-like behaviors in kynurenine 3-monooxygenase KO mice. A deficiency in kynurenine 3-monooxygenase appears to be implicated in antidepressant-responsive depression-like behaviors. In the kynurenine 3-monooxygenase KO mice, there are abnormal kynurenine pathway metabolites and monoamines. The abnormal monoamines in addition to the abnormal kynurenine pathway metabolites may play an important role in the pathophysiology of major depressive disorder Mus musculus
metabolism pivotal enzyme in kynurenine pathway Mus musculus